FORM 6-K

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Report of Foreign Private Issuer Pursuant to Rule 13a-16 under the Securities Exchange Act of 1934

For the month ended February, 2015

ICON plc

(Registrant's name)

0-29714 (Commission file number)

South County Business Park, Leopardstown, Dublin 18, Ireland (Address of principal executive offices)

Brendan Brennan, CFO
South County Business Park Leopardstown, Dublin 18, Ireland.
Brendan.Brennan@iconplc.com
00-353-1-291-2000

(Name, telephone number, email and/or facsmile number and address of Company contact person)

(Name, terephone number, eme	an and/or racsimile number and a	duress of Company Contact person)
Indicate by check mark whether the registrant fi	iles or will file annual reports und	der cover Form 20-F or Form 40-F.
	103 <u>A</u>	110
Indicate by check mark whether the registrant is	s submitting the Form 6-K in pap	per as permitted by Regulation S-T Rule 101(b)(1):
•	Yes	NoX
Ç		per as permitted by Regulation S-T Rule 101(b)(7):
	Yes	NoX
Indicate by check mark whether the registrant by information to the Commission pursuant to Rule		tained in this Form is also thereby furnishing the Exchange Act of 1934.
7	Yes	No <u>X</u>
If "Yes" is marked, indicate below the file numb	per assigned to the registrant in c	onnection with Rule 12g3-2(b):82 N/A

EXHIBIT LIST

Exhibit Description

99.1 ICON plc Press Release issued February 2, 2015

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

ICON plc

Date: February 2, 2015 /s/ Brendan Brennan

Brendan Brennan Chief Financial Officer

ICON to Acquire MediMedia Pharma Solutions

Extends ICON's leadership in commercialisation and market access services and brings new scientific communications capabilities

DUBLIN--(BUSINESS WIRE)--February 2, 2015--**ICON plc (NASDAQ:ICLR),** a global provider of outsourced development services to the pharmaceutical, biotechnology and medical device industries, today announced it has agreed, subject to certain customary closing conditions, to acquire MediMedia Pharma Solutions for a cash consideration of \$120 million. MediMedia Pharma Solutions is division of MediMedia USA and is owned by Vestar Capital Partners.

The acquisition strengthens ICON's expertise in scientific communications and market access and, together with ICON's existing Commercialisation and Outcomes practices, creates the industry's leading integrated scientific communications and market access solution.

Headquartered in Yardley, Pennsylvania, MediMedia Pharma Solutions includes *MediMedia Managed Markets* and *Complete Healthcare Communications*. *MediMedia Managed Markets* is a leading provider of strategic payer-validated market access solutions. *Complete Healthcare Communications* is one of the leading medical and scientific communication agencies working with medical affairs, commercial and brand development teams within life science companies. MediMedia Pharma Solutions has supported hundreds of development launches and in-market products, spanning over 40 therapeutic classes.

Commenting on the acquisition, Ciaran Murray, ICON CEO, said: "The need to demonstrate and communicate the value of new medicines is an important global healthcare trend. Through ICON's market leading commercialisation and outcomes group we are supporting our customers to maximise the value of their new drugs. Our acquisition of MediMedia Pharma Solutions deepens the expertise of this group and brings us outstanding scientific and medical communications capabilities."

Tim Search, President of MediMedia Pharma Solutions, commented, "The combination of the commercial, scientific, and market access expertise of MediMedia Pharma Solutions and ICON creates an unparalleled offering that can inform product investment decisions and establish and communicate product value. With the shift to evidence-based medicine and value-based pricing, we are excited about the expanded expertise and capabilities our relationship with ICON brings to our combined customers."

About ICON plc

ICON plc is a global provider of outsourced development services to the pharmaceutical, biotechnology and medical device industries. The Company specialises in the strategic development, management and analysis of programs that support clinical development - from compound selection to Phase I-IV clinical studies. ICON currently has 10,600 employees, operating from 83 locations in 38 countries.

Further information is available at www.iconplc.com

About MediMedia Pharma Solutions

MediaMedia Pharma Solutions is a combination of MediMedia Managed Markets and Complete HealthCare Communications.

MediMedia Managed Markets is a leading provider of strategic payer-validated market access solutions for the biopharmaceutical and medical device industries. Their comprehensive approach includes scientific analysis and assessment, research and insights, strategic development, tactical development, and program execution. Complete HealthCare Communications is one of the largest medical communication agencies and is a pioneer in publication services, providing strategic consulting, software solutions, and scientific communications to medical affairs teams for life sciences firms globally.

Further information is available at www.medimediamanagedmarkets.com and www.thechcgroup.com

About Vestar Capital Partners

Vestar Capital Partners is a leading U.S. middle-market private equity firm specializing in management buyouts and growth capital investments. Vestar invests and collaborates with incumbent management teams and private owners in a creative, flexible and entrepreneurial way to build long-term enterprise value.

Vestar targets equity investments in U.S.-based middle-market companies with enterprise values ranging from \$200 million to \$1 billion. Vestar has extensive experience investing across a wide variety of industries including Consumer, Healthcare, Digital Media, Information Services, Diversified Industries, and Financial Services. Since Vestar's founding in 1988, Vestar funds have completed more than 70 investments in companies with a total value of more than \$40 billion.

Further information is available at www.vestarcapital.com

This press release contains forward-looking statements. These statements are based on management's current expectations and information currently available, including current economic and industry conditions. These statements are not guarantees of future performance or actual results, and actual results, developments and business decisions may differ from those stated in this press release. The forward-looking statements are subject to future events, risks, uncertainties and other factors that could cause actual results to differ materially from those projected in the statements, including, but not limited to, the ability to enter into new contracts, maintain client relationships, manage the opening of new offices and offering of new services, the integration of new business mergers and acquisitions, as well as economic and global market conditions and other risks and uncertainties detailed from time to time in SEC reports filed by ICON, all of which are difficult to predict and some of which are beyond our control. For these reasons, you should not place undue reliance on these forward-looking statements when making investment decisions. The word "expected" and variations of such words and similar expressions are intended to identify forward-looking statements. Forward-looking statements are only as of the date they are made and we do not undertake any obligation to update publicly any forward-looking statement, either as a result of new information, future events or otherwise. More information about the risks and uncertainties relating to these forward-looking statements may be found in SEC reports filed by ICON, including its Form 20-F, F-1, S-8 and F-3, which are available on the SEC's website at http://www.sec.gov.

ICON/ICLR-F

CONTACT:

ICON plc
Investor Relations
1-888-381-7923
or
Brendan Brennan, + 353 –1-291-2000
Chief Financial Officer
or
Simon Holmes, + 353 –1-291-2000
EVP Investor Relations and Corporate Development
http://www.iconplc.com